Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection

Posted on August 3, 2015 by Graham R. Foster, Stephen Pianko, Ashley Brown, Daniel Forton, Ronald G. Nahass, Jacob George, Eleanor Barnes, Diana M. Brainard, Benedetta Massetto, Ming Lin, Bin Han, John G. McHutchison, G. Mani Subramanian, Curtis Cooper, Kosh Agarwal, BOSON Stud

We performed an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir plus ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naïve or -experienced patients with HCV genotype 3 infection.

This entry was posted in News. Bookmark the permalink.